<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02508467</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-554-1101</org_study_id>
    <secondary_id>2015-001662-26</secondary_id>
    <nct_id>NCT02508467</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety,
      tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic
      activity of BLU- 554 administered orally in patients with FGF19 IHC+ hepatocellular carcinoma
      (HCC). The study consists of 3 parts, a dose-escalation part (Part 1), an expansion part
      (Part 2) exploring a once daily (qd) dosing schedule at the recommended Phase 2 dose (RP2D),
      and a Part 3 expansion of the qd dosing schedule at the RP2D in TKI naive patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) on qd and bid schedules</measure>
    <time_frame>During cycle 1 (28 days) of treatment and will be determined by approximately 24 months after start of the study or earlier</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose of BLU-554 on qd and bid schedules</measure>
    <time_frame>At the end of every cycle (28 days) of treatment and will be determined by approximately 24 months after start of the study or earlier</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and changes in physical findings, vital signs, clinical laboratory results and ECG findings</measure>
    <time_frame>Every cycle (28 days) for approximately 24 months or earlier if patient terminates from the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of BLU-554 on qd and bid schedules</measure>
    <time_frame>Every cycle (28 days) up to cycle 4 and at end of treatment (approximately 24 months or earlier if patient terminates from the study)</time_frame>
    <description>Blood samples may be taken at pre-dose, and 0.5, 1, 2, 4, 6, 8 and 24 hrs post dose on Cycle 1 Day 1 and Cycle 1 Day 15, Pre-dose of Cycle 2 to 4, Day 1 and end of treatment (EOT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration of BLU-554 on qd and bid schedules</measure>
    <time_frame>Every cycle (28 days) up to cycle 4 and at end of treatment (approximately 24 months or earlier if patient terminates from the study)</time_frame>
    <description>Blood samples may be taken at pre-dose, and 0.5, 1, 2, 4, 6, 8 and 24 hrs post dose on Cycle 1 Day 1 and Cycle 1 Day 15, Pre-dose of Cycle 2 to 4, Day 1 and EOT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroblast growth factor 19 (FGF19) status in tumor tissue</measure>
    <time_frame>Cycle 2 (Day 56)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of FGF19 in blood and tumor samples</measure>
    <time_frame>Cycle 1 (Day 28)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary evidence of BLU-554 antineoplastic activity</measure>
    <time_frame>Screening, Day 1 of every odd numbered cycle starting with Cycle 3, End of treatment (at approximately 24 months or earlier if patient terminates from the study) and every three months post EOT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>BLU-554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BLU-554 capsules for oral administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLU-554</intervention_name>
    <arm_group_label>BLU-554</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Confirmed diagnosis of HCC by histological examination or by non-invasive criteria
             according to European Association for the Study of the Liver (EASL) or American
             Association for the Study of Liver Disease (AASLD) guidelines (Part 1, 2 and 3).

          -  For Part 1 and 2, the patient has unresectable disease and has been previously treated
             with sorafenib, has declined treatment with sorafenib, or does not have access to
             sorafenib.

          -  For Part 3, the patient has not received prior treatment with a TKI.

          -  Child-Pugh class A with no clinically apparent ascites

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  For Part 1, willing to provide archived tumor tissue (if available) and willing to
             undergo pre- and on-treatment tumor biopsy (if considered safe and medically feasible
             by the treating investigator)

          -  For Part 2 and 3, all patients must have an FGF19 IHC result available. Only FGF19
             IHC+ HCC patients will be eligible for Part 3.

        Key Exclusion Criteria:

          -  Central nervous system metastases

          -  Platelet count &lt;75,000/mL

          -  Absolute neutrophil count &lt;1000/mL

          -  Hemoglobin &lt;8 g/dL

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;5x the upper limit
             of normal (ULN)

          -  Total bilirubin &gt;2.5 mg/dL

          -  International normalized ratio (INR) &gt;2.3 or prothrombin time (PT) &gt;6 seconds above
             control

          -  Estimated (Cockroft-Gault formula) or measured creatinine clearance &lt;40 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Blueprint Medicines</last_name>
    <phone>617-714-6707</phone>
    <email>studydirector@blueprintmedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami - Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg University Mainz - University Medical Center</name>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatine</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Foundation - National Institute of Tumors</name>
      <address>
        <city>Milan</city>
        <zip>21033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Institute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Liverpool - Clatterbridge Cancer Centre</name>
      <address>
        <city>Bebington</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2015</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver cancer</keyword>
  <keyword>FGF19 gene amplification</keyword>
  <keyword>FGF19 overexpression</keyword>
  <keyword>FGF19 upregulation</keyword>
  <keyword>Cyclin D1 (CCND1) gene amplification</keyword>
  <keyword>Cyclin D1 (CCND1) copy number gain</keyword>
  <keyword>BLU-554</keyword>
  <keyword>FGFR4</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>Liver Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

